Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure

American Journal of Health-System Pharmacy

Volumn 64, Issue 9, 2007, Pages 931-936

  Granberry, Mark C ^a   Hawkins, Jason B ^b,c   Franks, Amy M ^c  

^a UNIVERSITY OF THE INCARNATE WORD   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Diabetes mellitus; Dosage; Drug interactions; Heart failure; Insulin; Insulins; Mechanism of action; Thiazolidinediones; Toxicity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; CLINICAL PHARMACY; DEATH; DIET; DRUG MECHANISM; EDEMA; ENDOTHELIAL DYSFUNCTION; EXERCISE; GLYCEMIC CONTROL; HEART FAILURE; HEART PROTECTION; HOSPITALIZATION; HUMAN; INSULIN RESISTANCE; LIVER TOXICITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; WEIGHT GAIN;

EID: 34247607648     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060446     Document Type: Review

References (39)

1. Nichols GA, Hillier TA, Erbey JR et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001; 24:1614-9.
2. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34:29-34.
3. Iribarren C, Karter AJ, Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103:2668-73.
4. Croft JB, Giles WH, Pollard RA et al. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med. 1999; 159:505-10.
5. Dries DL, Sweitzer NK, Drazner MH et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 2001; 38:421-8.
6. Mosterd A, Cost B, Hoes AW et al. The prognosis of heart failure in the general population. The Rotterdam Study. Eur Heart J. 2001; 22:1318-27.
7. Ingelsson E, Sundstrom J, Arnlov J et al. Insulin resistance and risk of congestive heart failure. JAMA. 2005; 294:334-41.
8. American Diabetes Association. ADA all about diabetes. www.diabetes.org/home. jsp (accessed 2006 Oct 23).
9. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003; 115(suppl 1): 42-8.
10. Martens FM, Visseren FL, Lemay J et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002; 62: 1463-80.
11. Nikolaidis LA, Levine TB. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure? Cardiol Rev. 2004; 12:158-70.
12. Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol. 2003; 92:50-60.
13. Wang CH, Weisel RD, Liu PP et al. Glitazones and heart failure: a critical appraisal for the clinician. Circulation. 2003; 107:1350-4.
14. St John Sutton M, Rendell M, Dandona P et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002; 25:2058-64.
15. Shiomi T, Tsutsui H, Hayashidani S et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002; 106:3126-32.
16. Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004; 27:2654-60.
17. Nishio K, Sakurai M, Kusuyama T et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2004; 27:2654-60.
18. Fonarow GC. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. Am Heart J. 2004; 148:551-8.
19. Akazawa S, Sun F, Ito M et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 2000; 23:1067-71.
20. Carey DG, Cowin GJ, Galloway GJ et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res. 2002; 10:1008-15.
21. Kelly IE, Han TS, Walsh K et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999; 22:288-93.
22. Mori Y, Murakawa Y, Okada K et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999; 22:908-12.
23. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med. 2003; 115(8, suppl 1):111-5.
24. Emoto M, Anno T, Sato Y et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 2001; 50:1166-70.
25. El Muayed M, Lavis VR, Safi HJ et al. Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring? Am J Cardiol. 2004; 93:600-2.
26. Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001; 24:1226-32.
27. Rosenstock J, Einhorn D, Hershon K et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002; 56:251-7.
28. Tang WH, Francis GS, Hoogwerf BJ et al. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003; 41:1394-8.
29. Ogino K, Furuse Y, Uchida K et al. Troglitazone improves cardiac function in patients with congestive heart failure. Cardiovasc Drugs Ther. 2005; 16:215-20.
30. Actos (pioglitazone hydrochloride) package insert. Osaka, Japan: Takeda Pharmaceutical Company; 2004 Aug.
31. Avandia (rosiglitazone maleate) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006 Jun.
32. Smooke S, Horwich TB, Fonarow GC et al. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005; 149:168-74.
33. Simpson SH, Majumdar SR, Tsuyuki RT et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006; 174:169-74.
34. Rajagopalan R, Rosenson RS, Fernandes AW et al. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther. 2004; 26:1400-10.
35. Delea TE, Edelsberg JS, Hagiwara M. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003; 226:2983-9.
36. Hartung DM, Touchette DR, Bultemeier NC et al. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a Medicaid claims-based case-control study. Pharmacotherapy. 2005; 25:1329-36.
37. Karter AJ, Ahmed AT, Liu J et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005; 22:986-93.
38. Masoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005; 111:583-90.
39. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomized controlled trial. Lancet. 2005; 366:1279-89.